Early participation in an HIV cohort study slows disease progression and improves survival

Journal of Internal Medicine

Volumn 244, Issue 6, 1998, Pages 479-487

  Battegay, M ^a   Wirz, M ^b   Steuerwald, M H ^a   Egger, M ^c,d,e  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e Canynge Hall ^*  (United Kingdom)

Author keywords

HIV positive

Indexed keywords

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEALTH CARE UTILIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL RATE;

ADULT; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SWITZERLAND;

EID: 0031798244     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1998.00392.x     Document Type: Article

References (36)

1. Veugelers PJ, Schechter MT, Tindall B, Moss AR, Kimberly AP, Craib KJP et al. Differences in time from HIV seroconversion to CD4+ lymphocyte end-points and AIDS in cohort of homosexual men. AIDS 1993; 7: 1325-9.
2. Phillips AN, Sabin CA, Elford J, Bofill M, Janossy G, Lee CA. Use of CD4 lymphocyte count to predict long term survival free of AIDS after HIV infection. Br Med J 1994; 309: 309-13.
3. McNeil AJ, Yap PL, Brettle RP, McColl M, Wyld R, Davidson S et al. Association of HLA types A1-B8-DR3 and B27 with rapid and slow progression of HIV disease. Quart J Med 1996; 89: 177-85.
4. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167-70.
5. Cozzi Lepri A, Pezzotti P, Dorrucci M, Phillips AN, Rezza G, the Italian Seroconversion Study, HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. Br Med J 1994; 309: 1537-42.
6. Phillips AN, Lee CA, Elford J, Webster A, Janossy G, Timms A et al. More rapid progression to AIDS in older HIV-infected people: the role of CD4+ T-cell counts. J AIDS Hum Retrovirol 1991; 4: 970-5.
7. Darby SC, Ewart DW, Giangrande PL, Spooner RJ, Rizza CR. Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. Lancet 1996; 347: 1573-9.
8. Members of the USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. Ann Intern Med 1996; 124: 348-68.
9. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996; 335: 1081-90.
10. Delta Coordinating Committee, Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283-91.
11. CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349: 1413-21.
12. Decks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA 1996; 277: 145-53.
13. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS et al. for the AIDS Clinical Trials Group 320 Study Team. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. New Engl J Med 1997; 337: 725-33.
14. Saag MS, Holodniy M, Kuritzkes DR. HIV viral load markers in clinical practice. Nature Med 1996; 2: 625-9.
15. Ho DD. Viral counts count in HIV infection. Science 1996; 272: 1124-5.
16. Kitahata MM, Koepsell TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EH. Physicians experience with the acquired immunodeficiency syndrome as a factor in patients' survival. New Engl J Med 1996; 334: 701-6.
17. Poznansky MC, Coker R, Skinner C, Hill A, Bailey S, Whitaker L et al. HIV positive patients first presenting with an AIDS defining illness: characteristics and survival. Br Med J 1995; 311: 156-8.
18. Ledergerber B, von Overbeck J, Egger M, Luethy R. The Swiss HIV cohort study: rationale, organization and selected baseline characteristics. Soz Praeventivmed 1994; 39: 387-94.
19. von Overbeck J, Egger M, Davey Smith G, Schoep M, Ledergerber B, Furrer H et al. Survival in HIV infection: do sex and category of transmission matter.? AIDS 1994; 8: 1307-13.
20. Centers for Disease Control, 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41: 1-20.
21. Egger M, von Overbeck J, Janin B, Francioli P. Evolution du spectre des infections opportunistes de 1987 à 1994: expérience de l'étude Suisse de cohorte (SHCS). Médecine et Hygiene 1996; 54: 306-10.
22. Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobson DM, Katzenstein DA et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. JAMA 1996; 276: 146-54.
23. Bucher HC, Griffith L, Guyatt GH, Opravil M. Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. J AIDS Hum Retrovirol 1997; 15: 104-14.
24. Pierce M, Crampton S, Henry D, Heifets L, La Marca A, Montecalvo M et al. A randomized trial of clarithromycin as prophylaxis against disseminaterd Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. New Engl J Med 1996; 335: 384-91.
25. Concorde Coordinating Committee, Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343: 871-81.
26. Egger M, Neaton JD, Phillips AN, Davey Smith G. Concorde trial of immediate vs. deferred zidovudine. Lancet 1994; 343: 1355.
27. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Br Med J 1997; 315: 1194-9.
28. Muñoz A, Schrager LK, Bacellar H, Speizer I, Vermund SH, Detels R et al. Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the multicenter AIDS cohort study: 1985-1991. Am J Epidemiol 1993; 137: 423-38.
29. Osmond D, Charlebois E, Lang W, Shiboski S, Moss A. Changes in AIDS survival time in two San Francisco chorts of homosexual men, 1983 to 1993. JAMA 1994; 271: 1083-7.
30. Graham NM, Zeger SL, Park LP, Vermund SH, Detels R, Rinaldo CR, Phair JP. The effects on survival of early treatment of human immunodeficiency virus infection infection. New Engl J Med 1992; 326: 1037-42.
31. Chaisson RE, Keruly J, Richman DD, Moore RD. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with xidovudine: the Zidovudine Epidemiology Group. Arch Int Med 1992; 152: 2009-13.
32. Phillips AN, Pezzotti P, Cozzi Lepri A, Rezza G. CD4 lymphocyte count as a determinant of the time from HIV seroconversion to AIDS and death from AIDS: evidence from Italian Seroconversion Study. AIDS 1994; 8: 1299-305.
33. Phillips AN, Sabin CA, Elford J, Bofill M, Janossy G, Lee CA. Acquired immunodeficiency syndrome (AIDS) risk in recent and long-standing human immunodeficiency virus type 1 (HIV-1)-infected patients with similar CD4 lymphocyte counts. Am J Epidemiol 1993; 138: 870-80.
34. Lindback S, Brostrom C, Karlsson A, Gaines H. Does symptomatic primary HIV-1 infection accelerate progression to CDC stage IV disease, CD4 count below 200 × 10 /L. AIDS, and death from AIDS? Br Med J 1994; 309: 1535-7.
35. Pantaleo G, Demarest JF, Schacker T, Vaccarezza M, Cohen OJ, Daucher M et al. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci USA 1997; 94: 254-8.
36. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature 1996; 384: 529-34.